Instrument Inactif

Communiqués Amylin Pharmaceuticals LLC

Actions

US0323461089

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

16/07/12	GSK annonce le rachat de Human Genome pour $3,0 milliards	RE
02/07/12	Wall Street termine sans grande tendance après les PMI	RE

Communiqués

09/08/12	Amylin Pharmaceuticals, Inc. : Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin	PU
12/07/12	Amylin Pharmaceuticals, Inc. : The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Amylin Pharmaceuticals, Inc. in Connection with the Sale of the Company to Bristol-Myers Squibb Corporation	BU
09/07/12	Amylin Pharmaceuticals, Inc. : Securities Lawyers at Goldfarb LLP Seeking More Money, Information for Stockholders of Amylin Pharmaceuticals, Inc.	PR
07/07/12	Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.	BU
03/07/12	Amylin Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.	PR
03/07/12	Amylin Pharmaceuticals, Inc. : Ryan & Maniskas, LLP Announces Investigation of Amylin Pharmaceuticals, Inc.	BU
02/07/12	Amylin Pharmaceuticals, Inc. : The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Amylin Pharmaceuticals, Inc. in Connection with the Sale of the Company to Bristol-Myers Squibb Corporation	BU
02/07/12	Amylin Pharmaceuticals, Inc. : Harwood Feffer LLP Announces Investigation of Amylin Pharmaceuticals, Inc.	PR
02/07/12	Amylin Pharmaceuticals, Inc. : Rigrodsky & Long, P.A. Announces Investigation Of Amylin Pharmaceuticals, Inc. Buyout	BU
02/07/12	Amylin Pharmaceuticals, Inc. : Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amylin Pharmaceuticals Inc.	BU
02/07/12	Amylin Pharmaceuticals, Inc. : Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.	PR
25/06/12	Amylin Pharmaceuticals, Inc. : New Clinical Data Analyses Show Metreleptin Reduced Blood Glucose and Triglyceride Levels in Patients with Rare Forms of Lipodystrophy	BU
09/06/12	Amylin Pharmaceuticals, Inc. : SYMLIN® Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range	BU
09/06/12	Amylin Pharmaceuticals, Inc. : BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes	BU
04/06/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present Data on BYDUREON™, BYETTA® and SYMLIN® at the American Diabetes Association 2012 Meeting	BU
29/05/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference and Goldman Sachs 33rd Annual Global Healthcare Conference	BU
08/05/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders	BU
30/04/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Deutsche Bank 37th Annual Health Care Conference	BU
26/04/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals Reports First Quarter 2012 Financial Results	BU
19/04/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Webcast First Quarter Results	BU
03/04/12	Amylin Pharmaceuticals, Inc. : Amylin Completes Biologics License Application for Metreleptin to Treat Diabetes and/or Hypertriglyceridemia in Patients With Rare Forms of Lipodystrophy	PR
23/03/12	Amylin Pharmaceuticals, Inc. : BYETTA® Approved for Use with Basal Insulin in Europe	PU
08/03/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals Announces Pricing of Public Offering of Common Stock	PR
08/03/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference	PR
07/03/12	Amylin Pharmaceuticals, Inc. : Amylin Pharmaceuticals Announces Public Offering of Common Stock	PR